Your browser doesn't support javascript.
loading
The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
Liu, Gan; Hu, Qifan; Peng, Shuguang; Ning, Hui; Mai, Jiajia; Chen, Xi; Tao, Minzhen; Liu, Qiang; Huang, Huiya; Jiang, Yun; Ding, Yanhua; Zhang, Xuegong; Gu, Jin; Xie, Zhen.
Afiliação
  • Liu G; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China; Beijing SyngenTech Co., LTD, Zhongguancun Life S
  • Hu Q; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China.
  • Peng S; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China.
  • Ning H; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China.
  • Mai J; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
  • Chen X; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China.
  • Tao M; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China.
  • Liu Q; Beijing SyngenTech Co., LTD, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
  • Huang H; Beijing SyngenTech Co., LTD, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
  • Jiang Y; Beijing SyngenTech Co., LTD, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
  • Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China. Electronic address: dingyanh@jlu.edu.cn.
  • Zhang X; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China; School of Life Sciences and School of Medicine,
  • Gu J; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China. Electronic address: jgu@tsinghua.edu.cn.
  • Xie Z; MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, 100084, China. Electronic address: zhenxie@tsinghua.edu.cn.
Cancer Lett ; 581: 216485, 2024 01 28.
Article em En | MEDLINE | ID: mdl-38008394
ABSTRACT
Oncolytic viruses are multifaceted tumor killers, which can function as tumor vaccines to boost systemic antitumor immunity. In previous study, we rationally designed a synthetic oncolytic adenovirus (SynOV) harboring a synthetic gene circuit, which can kill tumors in mouse hepatocellular carcinoma (HCC) models. In this study, we demonstrated that SynOV could sense the tumor biomarkers to lyse tumors in a dosage-dependent manner, and killed PD-L1 antibody resistant tumor cells in mouse model. Meanwhile, we observed SynOV could cure liver cancer and partially alleviate the liver cancer with distant metastasis by activating systemic antitumor immunity. To understand its high efficacy, it is essential to explore the cellular and molecular features of the remodeled tumor microenvironment (TME). By combining spatial transcriptome sequencing and single-cell RNA sequencing, we successfully depicted the remodeled TME at single cell resolution. The state transition of immune cells and stromal cells towards an antitumor and normalized status exemplified the overall cancer-suppressive TME after SynOV treatment. Specifically, SynOV treatment increased the proportion of CD8+ T cells, enhanced the cell-cell communication of Cxcl9-Cxcr3, and normalized the Kupffer cells and macrophages in the TME. Furthermore, we observed that SynOV could induce distant responses to reduce tumor burden in metastatic HCC patient in the Phase I clinical trial. In summary, our results suggest that SynOV can trigger systemic antitumor immunity to induce CD8+ T cells and normalize the abundance of immune cells to remodel the TME, which promises a powerful option to treat HCC in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Vírus Oncolíticos / Terapia Viral Oncolítica / Neoplasias Hepáticas Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Vírus Oncolíticos / Terapia Viral Oncolítica / Neoplasias Hepáticas Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2024 Tipo de documento: Article
...